Sugi Predict

Sugi Predict / Compounds / SCHEMBL829154

SCHEMBL829154

SCHEMBL829154

CS/C(N)=N/C(=O)c1nc(Cl)c(N)nc1N

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 11/20 0.69
▸ CYP1A2 P05177 6/20 0.69
▸ SLC9A5 Q14940 6/20 0.69
▸ TSHR P16473 5/20 0.69
▸ SLC9A1 P19634 5/20 0.69
▸ ALDH1A1 P00352 4/20 0.69
▸ CYP2D6 P10635 4/20 0.69
▸ KDM4E B2RXH2 3/20 0.69
▸ GLA P06280 3/20 0.69
▸ HPGD P15428 3/20 0.69
▸ HSD17B10 Q99714 3/20 0.69
▸ LMNA P02545 3/20 0.69
▸ CYP2C19 P33261 3/20 0.69
▸ GAA P10253 2/20 0.69
▸ FTO Q9C0B1 2/20 0.69
▸ OPRM1 P35372 2/20 0.69
▸ BLM P54132 2/20 0.69
▸ ADORA2A P29274 2/20 0.69
▸ SLC22A1 O15245 1/20 0.69
▸ HTR1A P08908 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2054482 1.00 PLAU (0.69) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL1586403 1.00 PLAU (0.69) PLAUCYP1A2SLC9A5TSHRSLC9A1
Iodide SCHEMBL1587056 0.98 PLAU (0.67) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL14156429 0.88 PLAU (0.53) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL13104159 0.86 PLAU (0.71) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL12903457 0.84 PLAU (0.64) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL12944839 0.83 PLAU (0.48) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL14115628 0.83 PLAU (0.46) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL16200815 0.83 PLAU (0.46) PLAUCYP1A2SLC9A5TSHRSLC9A1
SCHEMBL13979955 0.83 PLAU (0.68) PLAUCYP1A2SLC9A5TSHRSLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578042-B2 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide PARION SCIENCES, INC. (US) 2023-02-14 — — US disclosed
WO-2023283639-A1 EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF LUNG THERAPEUTICS, INC. (US) 2023-01-12 — — WO disclosed
US-20210024471-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE PARION SCIENCES, INC. (US) 2021-01-28 — — US disclosed
US-10752597-B2 3,5-diamino-6-chloro-N—(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide PARION SCIENCES, INC. (US) 2020-08-25 — — US disclosed
EP-3693361-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTA-HYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE Parion Sciences, Inc. (US) 2020-08-12 — — EP disclosed
US-20190308943-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS PARION SCIENCES, INC. (US) 2019-10-10 — — US disclosed
EP-3323812-B1 ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES INC (US) 2019-08-14 — — EP disclosed
US-20190241528-A1 SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2019-08-08 — — US disclosed
EP-2897940-B1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2019-05-01 — — EP disclosed
US-10246425-B2 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds PARION SCIENCES, INC. (US) 2019-04-02 — — US disclosed
US-20090076273-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2009-03-19 — — US disclosed
US-20090076273-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2009-03-19 — — US disclosed
US-20080177072-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2008-07-24 — — US disclosed
US-20080177072-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2008-07-24 — — US disclosed
US-20080171879-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2008-07-17 — — US disclosed
US-20080171879-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2008-07-17 — — US disclosed
US-7399766-B2 Soluble amide & ester pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. (US) 2008-07-15 — — US disclosed
US-20080096896-A1 Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers PARION SCIENCES, INC. (US) 2008-04-24 — — US disclosed
US-20070021439-A1 Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. 2007-01-25 — — US disclosed
US-20070021439-A1 Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. 2007-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096896-A1 Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers HCN4, CACNA1B, SCN5A PLAU 4047/4885CYP1A2 2550/4885SLC9A5 112/4885
US-20080171879-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS SCN2A, CACNA1B, HCN4 PLAU 2428/4885CYP1A2 2112/4885SLC9A5 100/4885
US-20210024471-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE CFTR, ELANE, IL5 PLAU 336/4885CYP1A2 1315/4885SLC9A5 251/4885
US-20190308943-A1 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS CFTR, SCNN1B, SCN5A PLAU 1521/4885CYP1A2 3142/4885SLC9A5 12/4885
US-11578042-B2 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide CFTR, ELANE, IL5 PLAU 336/4885CYP1A2 1315/4885SLC9A5 251/4885
US-10752597-B2 3,5-diamino-6-chloro-N—(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide CFTR, ELANE, IL5 PLAU 355/4885CYP1A2 1311/4885SLC9A5 235/4885
US-20080177072-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS SCN2A, CACNA1B, HCN4 PLAU 2428/4885CYP1A2 2112/4885SLC9A5 100/4885
US-20070021439-A1 Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers KCNN2, KCNN1, KCNN3 PLAU 1443/4885CYP1A2 1871/4885SLC9A5 513/4885
US-10246425-B2 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds CFTR, SCNN1B, SCN5A PLAU 1521/4885CYP1A2 3142/4885SLC9A5 12/4885
US-20090076273-A1 SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS SCN2A, CACNA1B, HCN4 PLAU 2428/4885CYP1A2 2112/4885SLC9A5 100/4885
US-20190241528-A1 SODIUM CHANNEL BLOCKERS HCN4, SCN2B, SCN5A PLAU 3471/4885CYP1A2 2573/4885SLC9A5 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.